Anavex Life Sciences Corp (AVXL) Stock Analysis

Anavex Life Sciences Corp (AVXL) is a publicly traded company in the HEALTHCARE sector. It trades at $2.79, carries a market capitalization of $276.16M. This page summarizes the public market data, fundamentals, and frequently asked questions for AVXL, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $2.79
• Market Cap: $276.16M
• EPS: $-0.46
• 52-Week High: $13.99
• 52-Week Low: $2.61

Market Sentiment

Anavex Life Sciences Corp currently has a Bearish sentiment score of -0.48.

About Anavex Life Sciences Corp

Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company headquartered in New York, dedicated to pioneering effective therapies for neurodegenerative diseases, particularly Alzheimer's and Parkinson's. Leveraging its proprietary drug discovery platform, Anavex is advancing a robust pipeline of innovative drug candidates that target the root causes of these disorders. The company's commitment to precision medicine is supported by extensive preclinical and clinical data, as well...

GNG Research Analysis

GNG Research scores Anavex Life Sciences Corp (AVXL) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for AVXL.

Frequently Asked Questions

Does AVXL pay dividends?

Anavex Life Sciences Corp (AVXL) does not currently pay a regular dividend.

What is AVXL's market cap?

Anavex Life Sciences Corp (AVXL) has a market capitalization of $276.16M with a current stock price of $2.79.